PROLENSA®

PART D COUPON PROGRAM

BAUSCH + LOMB

PAY NO MORE THAN $60*

If your out-of-pocket cost for PROLENSA® exceeds $60, Bausch + Lomb may be able to help.

Most eligible patients pay **$60** out-of-pocket for your prescription fill of PROLENSA® and receive up to **$195** off your remaining expenses

To obtain your PROLENSA® Part D Coupon Program card, please visit
www.prolensapartdcoupon.com

The PROLENSA® Part D Coupon Program is sponsored by Bausch + Lomb and designed to reduce your out-of-pocket cost for PROLENSA® if your Medicare Part D plan does not cover the product or you opt out of using your prescription benefit in conjunction with this offer. If you have questions related to this program, please call **1-800-706-5160**.

*Offer varies at cash-only pharmacies, see reverse for details

PROLENSA®
(bromfenac ophthalmic solution) 0.07%

POWERED BY COMP®

PROLENSA® Part D Coupon Program

To obtain your card, go to
www.prolensapartdcoupon.com

- PROLENSA® Part D Coupon Program card can only be used by eligible patients up to 6 times for PROLENSA® (bromfenac ophthalmic solution) 0.07% before the end of the calendar year, and reduces the patient's out-of-pocket costs for PROLENSA® to no more than $60 for each qualifying prescription. Maximum Bausch + Lomb contribution is $195 per prescription. This card is not insurance.
- PLEASE NOTE: Regardless of how many PROLENSA® Part D Coupon Program cards you receive or print, you may only use the card and pay no more than $60 for an eligible prescription, on or before December 31, 2015. Maximum Bausch + Lomb contribution is $195 per prescription.
- Terms and Conditions
- PROLENSA® Part D Coupon Program card is valid for a reduction in an eligible patient's out-of-pocket cost to no more than $60 on each qualifying prescription for PROLENSA®.
- Maximum Bausch + Lomb contribution is $195 per prescription.
- At cash-only pharmacies (i.e., those pharmacies not accepting insurance) all patients are responsible for the first $75 of out-of-pocket expense for each PROLENSA® prescription and then, Bausch + Lomb will be responsible for the remaining out-of-pocket expenses up to $160 per eligible prescription fill of PROLENSA®. Patient will be responsible for all additional costs and expenses for PROLENSA® after application of this offer including any applicable taxes.
- You must have prescription drug insurance through a Medicare Part D or Medicare Advantage prescription drug plan.
- You must agree to not seek reimbursement from your Medicare or Medicare Advantage prescription plan for your out-of-pocket costs for PROLENSA® purchased with the card.
- You must also agree not to count the cost of PROLENSA® toward your deductible or true out-of-pocket cost.
- You must notify your prescription plan that you have purchased PROLENSA® outside of your benefit by sending the form letter provided by Bausch + Lomb at www.prolensapartdcoupon.com
- Program is not valid for any patients with commercial / private insurance, uninsured / cash paying patients, or patients with prescription coverage under any other federal or state health program such as Medicaid or TRICARE.
- No other purchase necessary.
- PROLENSA® Part D Coupon Program card is not transferable. No substitutions are permitted. Cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer not already associated with this offer.
- PROLENSA® Part D Coupon Program card is not insurance.
- Patients participating in Medicare Part D or a Medicare Advantage prescription drug plan who use the PROLENSA® Part D Coupon Program card must agree to the following conditions:
- Patient must agree to not seek reimbursement from their Medicare or Medicare Advantage prescription plan for their out-of-pocket costs for PROLENSA® purchased with the card.
- Patient must also agree not to count the cost of PROLENSA® toward their deductible or true out-of-pocket cost.
- Patient must notify his/her prescription plan that he/she has purchased PROLENSA® outside his/her benefit by sending the form letter provided by Bausch + Lomb at www.prolensapartdcoupon.com
- The patient must purchase all of his/her prescriptions for PROLENSA® during the calendar year with the card and the patient must not use his/her Medicare Part D benefit for PROLENSA®, if the patient benefits were to change during the calendar year.
- PROLENSA® Part D Coupon Program card can be used only by eligible United States residents at participating eligible retail pharmacies in the United States. Product must originate from the United States.
- PROLENSA® Part D Coupon Program card cannot be used at mail-order pharmacies.
- PROLENSA® Part D Coupon Program card is the property of Bausch + Lomb and must be turned in on request.
- It is illegal to sell, purchase, trade, or counterfeit, or offer to sell, purchase trade, or counterfeit the PROLENSA® Part D Coupon Program card. Void if reproduced. Void where prohibited by law, taxed, or restricted.
- Bausch + Lomb reserves the right to rescind, revoke, or amend this offer at any time without notice.
- Data related to your redemption of the PROLENSA® Part D Coupon Program card may be collected, analyzed, and shared with Bausch + Lomb, for market research and other purposes related to assessing patient savings programs. Data shared with Bausch + Lomb will be aggregated and de-identified, meaning it will be combined with data related to other card redemptions and will not identify you.
- Expiration Date: 12/31/15

BAUSCH+LOMB

BAUSCH + LOMB

PROLENSA®

(bromfenac ophthalmic solution) 0.07%

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PROLENSA™ (bromfenac ophthalmic solution) 0.07% safely and effectively. See full prescribing information for PROLENSA™ ophthalmic solution.

PROLENSA™ (bromfenac ophthalmic solution) 0.07%
Initial U.S. Approval: 1997

----------INDICATIONS AND USAGE ----------

PROLENSA is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. (1)

---------- DOSAGE AND ADMINISTRATION ----------

Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post-surgery. (2.1)

---------- DOSAGE FORMS AND STRENGTHS ----------

Topical ophthalmic solution: bromfenac 0.07% (3)

----------CONTRAINDICATIONS ----------

None (4)

---------- WARNINGS AND PRECAUTIONS ----------

- Sulfite Allergic Reactions (5.1)
- Slow or Delayed Healing (5.2)
- Potential for cross-sensitivity (5.3)
- Increase bleeding of ocular tissues (5.4)
- Corneal effects including keratitis (5.5)
- Contact Lens Wear (5.6)

---------- ADVERSE REACTIONS ----------

The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-323-0000, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION

Revised: 4/2013

FULL PRESCRIBING INFORMATION: CONTENTS*

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

PROLENSA™ (bromfenac ophthalmic solution) 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

One drop of PROLENSA ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.

2.2 Use with Other Topical Ophthalmic Medications

PROLENSA ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cyclopegics, and mydriatics. Drops should be administered at least 5 minutes apart.

3 DOSAGE FORMS AND STRENGTHS

Topical ophthalmic solution: bromfenac 0.07%

4 CONTRAINDICATIONS

None

5 WARNINGS AND PRECAUTIONS

5.1 Sulfite Allergic Reactions

Contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

5.2 Slow or Delayed Healing

All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

5.3 Potential for Cross-Sensitivity

There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

5.4 Increased Bleeding Time

With some NSAIDs, including bromfenac, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

It is recommended that PROLENSA ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

5.5 Keratitis and Corneal Reactions

Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health.

Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

5.6 Contact Lens Wear

PROLENSA should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of PROLENSA. The preservative in PROLENSA, benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA.

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions following use of PROLENSA following cataract surgery include: anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. These reactions were reported in 3 to 8% of patients.